CELL AND GENE THERAPY

Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board

Elastrin Therapeutics Inc. | January 17, 2022

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board. The Board is comprised of leading industry and university experts in cardiovascular research and clinical development. Former CMO of Elastrin Therapeutics, Dr. Pedro M. Quintana Diez, will act as chairman. Elastrin Therapeutics’ lead asset ELT-001 is an EDTA-loaded nanoparticle conjugated with a proprietary monoclonal antibody for the treatment of vascular calcification.

We are fortunate to work with such an amazing group of medical scientists, cardiovascular experts and pharma executives on our Scientific Advisory Board,” said Dr. Matthias Breugelmans, CEO of Elastrin Therapeutics. “The members bring a remarkable understanding of cardiovascular research, as well as deep expertise in the development of clinical drugs.” “Elastrin is a prime example of what Kizoo is looking for in its investments: Not delaying an age-related disease but reversing it,” 

 Patrick Burgermeister, Partner at Kizoo Technology Capital and member of Elastrin Therapeutics’ Board of Directors


Elastrin Therapeutics’ Scientific Advisory Board is comprised of:

Prof. Charles O'Neill, MD: Dr. O’Neill has had an active basic and clinical research program in vascular calcification for the past 20 years and has published over 45 articles on this subject. As a practicing nephrologist, he has a particular interest in vascular calcification in patients with chronic kidney disease. Current research is aimed at approaches to assess reversibility of calcification in animal models and to slow progression of calcification by altering hemodialysis prescription in clinical trials.

Prof. Elena Aikawa, MD, PhD: Dr. Elena Aikawa is a Professor of Medicine at Harvard Medical School, and the Naoki Miwa Distinguished Chair in Cardiovascular Medicine and the Director of Heart Valve Translational Research Program at Brigham and Women’s Hospital. She was at the forefront in the discovery of inflammation-dependent mechanisms of cardiovascular calcification. Her studies contributed to the discovery of calcifying extracellular vesicles as a precursor of microcalcification.

Prof. Frank Rutsch, MD: Frank Rutsch is an Associate Professor in Pediatrics at Münster University Children’s Hospital, Münster, Germany. After a postdoctoral research fellowship at the University of California, San Diego, he became the leader of an independent research group at Münster University Children’s Hospital in 2004. Dr. Rutsch’s main research interests are focused on the discovery of the underlying genetic defects and translational aspects in rare pediatric metabolic and autoimmune disorders.

Dr. Klaus-Dieter Langner: Klaus-Dieter Langner is a life science expert with more than 32 years of experience in pharmaceutical industry. Klaus started his career as research scientist at Behringwerke/Hoechst focusing on the expression of recombinant human plasma proteins and immunomodulators. After 12 years, he moved to Grünenthal where he was appointed as Head of Research. In his last position, Klaus acted as Chief Scientific Officer and Member of the Corporate Executive Board.

Prof. Linda Hands, MD: Linda Hands was appointed Clinical Reader in the University of Oxford and Honorary Consultant Vascular surgeon in 1992 after training in London, Oxford and Chicago. She was Clinical Director of Vascular and cardiothoracic surgery for three years and also served on the Health Authority and a NICE committee. Linda retired in late 2017 as Associate Professor and remain an Hon. Emeritus Professor at the John Radcliffe Hospital Oxford and Emeritus Fellow of Green College, Oxford.

Dr. Pedro M. Quintana Diez, M.D.: Pedro is an internal medicine doctor with over 20 years of clinical development experience in the international biotech and pharmaceutical industry. Prior to joining Elastrin Therapeutics, Pedro served as CMO of Sensory Sciences LLC and held VP and leadership positions at Grunenthal, Abbvie and ParinGenix. Pedro managed Phase II and III developments in cardiovascular and lung diseases. His experience submitting INDs and CTAs will add further value to the company’s pipeline.

Dr. Yuri Martina, MD, MBA: Yuri has more than 20 years of experience and a strong track record in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US. During his career, Yuri has worked actively in different therapeutic areas and he has led teams bringing multiple compounds from pre-clinical phase into clinical studies in both Europe and US, and achieved multiple successful NDA and MAA submissions and approvals.

About Elastrin Therapeutics Inc.
Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University. The team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.

About KIZOO
Kizoo provides seed and follow-on financing with a focus on rejuvenation biotech. Having been entrepreneurs, VC, and mentors in both high-growth tech and biotech companies ourselves for many years with multiple exits and massive value created for the founders, Kizoo now brings this experience to the emerging field of rejuvenation biotech. We see it as a young industry that will eventually outgrow today's largest technology markets.

Spotlight

Welcome to Sheel Biotech Limited, established in the year 1991, we are a leading manufacturer, supplier, trader, service provider of Floriculture & Organic Farming. Our offered agro supplements and systems such as Floriculture Product, Green House, Organic Farming are widely acclaimed by the clients. We have ensured that our offered green houses are able to create favorable growth environment for the crops. Further, our offered green houses are able to control the temperature, humidity and sunlight for the specific cultivation needs of crops.

Spotlight

Welcome to Sheel Biotech Limited, established in the year 1991, we are a leading manufacturer, supplier, trader, service provider of Floriculture & Organic Farming. Our offered agro supplements and systems such as Floriculture Product, Green House, Organic Farming are widely acclaimed by the clients. We have ensured that our offered green houses are able to create favorable growth environment for the crops. Further, our offered green houses are able to control the temperature, humidity and sunlight for the specific cultivation needs of crops.

Related News

RESEARCH

Cedilla Therapeutics Expands Leadership Team with Key Appointments Across R&D And Finance

Cedilla Therapeutics | November 17, 2021

Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the clinic and continues to develop a broad portfolio of small molecule medicines that target key oncogenic drivers. “We are delighted to expand our team with these key hires, who share our passion and commitment to developing targeted medicines that conditionally modulate proteins in their functional state. We look forward to Joshua and Chris’ many contributions as we continue to explore the power of our novel approach to access historically undruggable cancer drivers, advance our lead conditional inhibitor programs targeting TEAD and CDK2 into clinical development, and ultimately build Cedilla into a fully integrated organization and leader in precision medicine.” Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics Joshua Murtie, Ph.D., has been appointed Vice President of Biology. Dr. Murtie brings over ten years of industry experience to Cedilla. He worked most recently as Senior Director at Servier Pharmaceuticals, where he oversaw cancer biology, in vivo pharmacology and early-stage program management at the company’s U.S. research site. Earlier, he spent nearly seven years at Agios Pharmaceuticals in roles of increasing responsibility, ultimately serving as Senior Director and Head of Cancer Biology, with responsibility for the strategic oversight of the company’s cancer biology portfolio from early target discovery to translational research. Prior to Agios Pharmaceuticals, Dr. Murtie worked as an investigator at Sanofi and Novartis. He holds a Ph.D. in molecular and cell biology from the Uniformed Services University of the Health Sciences and completed his research fellowship at Harvard Medical School. “I am thrilled to join Cedilla, particularly as we prepare to advance our lead programs, targeting TEAD and CDK2, into investigational new drug application-enabling studies next year,” said Dr. Murtie. “Both TEAD and CDK2 are well-known yet elusive cancer targets, which, if drugged successfully, could benefit the lives of patients living with a broad range of solid tumors. I am incredibly impressed by the collaborative and innovative culture at Cedilla and look forward to working closely with the team to translate our research efforts into precision therapies for patients in need.” Chris Lindblom has been appointed Vice President of Finance. Over the course of his 19 years in the biotechnology industry, Mr. Lindblom has crafted long-range financial plans for public and private companies and played a key role in helping companies raise capital through private equity rounds, venture debt deals and public offerings. Prior to joining Cedilla, Mr. Lindblom served as Vice President of Finance at IFM Therapeutics, Cogen Immune Medicine (through its merger with Torque Therapeutics to form Repertoire Immune Medicines) and Warp Drive Bio (through its acquisition by Revolution Medicines). Earlier, Mr. Lindblom held various senior finance roles at Millennium Pharmaceuticals, including through the commercial launch of VELCADE®, and at Infinity Pharmaceuticals. He also served as Vice President of Finance at OvaScience and Senior Vice President of Finance and Administration at BIND Therapeutics. Mr. Lindblom holds an MBA from Boston College and a B.S. in accounting from Syracuse University. He is also a CPA. “Since its founding, Cedilla has attracted a strong team, including leading scientists and advisors and a robust investor syndicate, to support its mission to bring a new dimension to precision oncology and deliver medicines that can offer profound benefits to patients,” said Mr. Lindblom. “I am honored to take on this role and eager to partner with my new colleagues as we continue building Cedilla for its next phase of growth.” About Cedilla Therapeutics Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team.

Read More

INDUSTRY OUTLOOK

Expanding Diagnostics Business: SCHOTT Signs Agreement to Acquire Applied Microarrays Inc.

Applied Microarrays Inc. | September 30, 2021

SCHOTT MINIFAB, a subsidiary of SCHOTT that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, has had a long-standing close customer relationship with Applied Microarrays Inc. (AMI). Together, they develop biotech substrates for diagnostics applications. The expertise of AMI will further strengthen SCHOTT’s ability to offer a single-source contract manufacturing solution. The deal is expected to close in early October. Through this acquisition, SCHOTT MINIFAB significantly expands its biosensor printing capabilities. This is of particular importance as demand is growing for the manufacturing of point-of-care microarray consumables, especially in applications such as infectious disease detection. “We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products. With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products.” - Greg Wolters, Head of SCHOTT MINIFAB. AMI will soon be moving to a larger facility in the Phoenix, Arizona area. Its new location will greatly increase SCHOTT’s manufacturing footprint in the United States to serve its global customer base. Pioneering – responsibly – together These attributes characterize SCHOTT as a manufacturer of high-tech materials based on specialty glass. Founder Otto Schott is considered its inventor and became the pioneer of an entire industry. Always opening up new markets and applications with a pioneering spirit and passion – this is what has driven the #glasslovers at SCHOTT for more than 130 years. Represented in 34 countries, the company is a highly skilled partner for high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace. In the fiscal year 2020, its 16,500 employees generated sales of 2.24 billion euros. With the best teams, supported by the best digital tools, the group intends to continue to grow. SCHOTT AG is owned by the Carl Zeiss Foundation, one of the oldest foundations in Germany. It uses the Group's dividends to promote science. As a foundation company, SCHOTT has anchored responsibility for employees, society and the environment deeply in its DNA. The goal is to become a climate-neutral company by 2030. About Applied Microarrays (AMI) AMI is a company headquartered in Tempe, AZ, which designs, optimizes and manufactures DNA and protein biosensors, and other microarrays on glass, plastic and semiconductors. AMI operates under ISO 9001 and ISO 13485 certification. Since acquiring GE Healthcare’s microarray business in 2007, AMI has evolved to become a full service provider for RUO and Dx devices.

Read More

CELL AND GENE THERAPY

Ginkgo Bioworks Launches Cell Development Kit Service for Standardized, Low-Cost Entry to its Cell Programming Platform

ginkgo biowork | November 11, 2021

ginkgo biowork the leading horizontal platform for cell programming, announced the launch of its Cell Development Kits (CDKs) service. CDKs provide streamlined access to the company's platform for aspiring cell developers to program cells to tackle the biggest challenges facing society. The first CDKs to launch are focused on protein expression programs. The service provides developers access to the toolkit needed to get started developing commercial proteins, including pre-engineered host cells optimized for protein production, specialized equipment, automation capabilities, genetic engineering expertise, insights garnered from Ginkgo's codebase and the applicable infrastructure to design, build and test a custom microbe. Ginkgo's CDKs are designed to cut the cost of launching a cell program and speed up development timelines to build engineered microbes, for example, to determine whether a protein may be successfully and commercially produced. The service is also designed to enable customers to prototype their idea in phases, with each phase providing data that can inform the customer's project and business strategy. By simplifying the pathway for companies to get started on the Ginkgo platform with standard terms, a phased approach, low costs—starting at $100,000 for protein expression projects—and clear deliverables, the CDK can help derisk projects prior to full scale technical development. "We believe engineering biology holds tremendous potential to revolutionize industries and our customers are using it to develop solutions ranging from alternative food proteins and vaccine ingredients to biodegradable plastics and sustainable chemicals But biology is still complex and highly variable, making the barrier to entry too high for many of the product developers that are out there with an idea they want to bring to the world. By providing these researchers, entrepreneurs and dreamers with the resources to realize their proof of concept, we're able to support the synthetic biology ecosystem to keep pushing the envelope on innovation." Jason Kelly, CEO of Ginkgo Bioworks If you are a developer interested in learning more about being in the next batch of CDK projects to launch, reach out to the Ginkgo team. Ginkgo will also be hosting an informational virtual event, Grow with Ginkgo: You're a Cell Developer, for prospective cell developers that are interested in learning more about the CDK on Thursday, Nov. 11 from 10 a.m.-12 p.m. ET. About Ginkgo Bioworks Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the launch and potential benefits of Ginkgo's "Cell Development Kits" (CDKs) service and the potential of Ginkgo's cell programming platform generally. These forward-looking statements generally are identified by the words "believe," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the effect of the business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business and changes in the combined capital structure, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, and (vi) the risk of downturns in demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's current report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on September 20, 2021 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Read More